Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis

다국어 초록 (Multilingual Abstract)

Objective: To evaluate the efficacy and safety of systematic lymph node dissection (SyLND) at the time of interval debulking surgery (IDS) for advanced epithelial ovarian cancer (AEOC). Methods: Systematic literature review of studies including AEOC patients undergoing SyLND versus selective lymph node dissection (SeLND) or no lymph node dissection (NoLND) after neoadjuvant chemotherapy (NACT). Primary endpoints included progression-free survival (PFS) and overall survival (OS). Secondary endpoints included severe postoperative complications, lymphocele, lymphedema, blood loss, blood transfusions, operative time, and hospital stay. Results: Nine retrospective studies met the eligibility criteria, involving a total of 1,660 patients: 827 (49.8%) SyLND, 490 (29.5%) SeLND, and 343 (20.7%) NoLND. The pooled estimated hazard ratios (HR) for PFS and OS were, respectively, 0.88 (95% confidence interval [CI]=0.65–1.20; p=0.43) and 0.80 (95% CI=0.50–1.30; p=0.37). The pooled estimated odds ratios (ORs) for severe postoperative complications, lymphocele, lymphedema, and blood transfusions were, respectively, 1.83 (95% CI=1.19–2.82; p=0.006), 3.38 (95% CI=1.71– 6.70; p<0.001), 7.23 (95% CI=3.40–15.36; p<0.0001), and 1.22 (95% CI=0.50–2.96; p=0.67). Conclusion: Despite the heterogeneity in the study designs, SyLND after NACT failed to demonstrate a significant improvement in PFS and OS and resulted in a higher risk of severe postoperative complications.

참고문헌 (Reference)

1 Di Donato V, "Trends in mortality after primary cytoreductive surgery for ovarian cancer : a systematic review and metaregression of randomized clinical trials and observational studies" 24 : 1688-1697, 2017

2 Song N, "Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer" 29 : 761-767, 2019

3 Pereira A, "The role of lymphadenectomy in node-positive epithelial ovarian cancer" 22 : 987-992, 2012

4 Chan JK, "The potential therapeutic role of lymph node resection in epithelial ovarian cancer : a study of 13918 patients" 96 : 1817-1822, 2007

5 Eoh KJ, "The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy" 116 : 329-336, 2017

6 Zhou J, "The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer : a systematic review and meta-analysis" 46 : 718-726, 2016

7 Eisenkop SM, "The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer" 82 : 143-149, 2001

8 Clavien PA, "The Clavien-Dindo classification of surgical complications : five-year experience" 250 : 187-196, 2009

9 Reuss A, "TRUST : Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer(ENGOT ov33/AGO-OVAR OP7)" 29 : 1327-1331, 2019

10 Fagotti A, "Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery : a double-institution case-control study" 19 : 3522-3527, 2012

11 Gao J, "Systematic lymphadenectomy in the treatment of epithelial ovarian cancer : a meta-analysis of multiple epidemiology studies" 45 : 49-60, 2015

12 Kim HS, "Systematic lymphadenectomy for survival in epithelial ovarian cancer : a meta-analysis" 20 : 520-528, 2010

13 Panici PB, "Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer : a randomized clinical trial" 97 : 560-566, 2005

14 Chang SJ, "Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer : a meta-analysis" 130 : 493-498, 2013

15 Bristow RE, "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era : a meta-analysis" 20 : 1248-1259, 2002

16 Lopes A, "Role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high-grade serous ovarian carcinoma" 47 : 2737-2744, 2021

17 He M, "Role of lymphadenectomy during interval debulking surgery performed after neoadjuvant chemotherapy in patients with advanced ovarian cancer" 11 : 646135-, 2021

18 Benoit L, "Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer" 48 : 275-282, 2022

19 Maggioni A, "Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis" 95 : 699-704, 2006

20 Sterne JA, "ROBINS-I : a tool for assessing risk of bias in non-randomised studies of interventions" 355 : i4919-, 2016

21 Wang Y, "Prognostic significance of systematic lymphadenectomy in patients with optimally debulked advanced ovarian cancer : a meta-analysis" 10 : 86-, 2020

22 Chang SJ, "Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer" 126 : 381-386, 2012

23 Kehoe S, "Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS) : an open-label, randomised, controlled, non-inferiority trial" 386 : 249-257, 2015

24 Di Donato V, "Preoperative frailty assessment in patients undergoing gynecologic oncology surgery : a systematic review" 161 : 11-19, 2021

25 Knobloch K, "Preferred reporting items for systematic reviews and meta-analyses(PRISMA)statement and publication bias" 39 : 91-92, 2011

26 du Bois A, "Potential role of lymphadenectomy in advanced ovarian cancer : a combined exploratory analysis of three prospectively randomized phase III multicenter trials" 28 : 1733-1739, 2010

27 Fagotti A, "Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load(SCORPION trial) : final analysis of peri-operative outcome" 59 : 22-33, 2016

28 Armstrong DK, "Ovarian cancer, version 2. 2020, NCCN clinical practice guidelines in oncology" 19 : 191-226, 2021

29 National Comprehensive Cancer Network, "Ovarian cancer (version 1.2022)" National Comprehensive Cancer Network

30 Vergote I, "Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer" 363 : 943-953, 2010

31 Di Donato V, "Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer" 161 : 4-10, 2021

32 Luyckx M, "Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice : a Retrospective French Multicentric Study" 22 : 1337-1343, 2012

33 Tatsuyuki Chiyoda ; Manabu Sakurai ; Toyomi Satoh ; Satoru Nagase ; Mikio Mikami ; Hidetaka Katabuchi ; Daisuke Aoki, "Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis" 대한부인종양학회 31 (31): 1-13, 2020

34 Berek JS, "Lymph node-positive stage IIIC ovarian cancer : a separate entity?" 19 (19): S18-S20, 2009

35 Tangjitgamol S, "Interval debulking surgery for advanced epithelial ovarian cancer" 4 : CD006014-, 2013

36 Schwartz L, "Impact of pelvic and para-aortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy" 35 : 5503-5509, 2015

37 Bund V, "Impact of lymphadenectomy on survival of patients with serous advanced ovarian cancer after neoadjuvant chemotherapy : a French national multicenter study(FRANCOGYN)" 9 : 2427-, 2020

38 Colombo N, "ESMO-ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†" 30 : 672-705, 2019

39 Onda T, "Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial : Japan Clinical Oncology Group Study JCOG0602" 64 : 22-31, 2016

40 Higgins JP, "Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)" Cochrane

41 Haruko Iwase ; Toshio Takada ; Chiaki Iitsuka ; Hidetaka Nomura ; Akiko Abe ; Tomoko Taniguchi ; Ken Takizawa, "Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients" 대한부인종양학회 26 (26): 303-310, 2015

42 Kontopantelis E, "A re-analysis of the Cochrane Library data : the dangers of unobserved heterogeneity in meta-analyses" 8 : e69930-, 2013

43 Harter P, "A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms" 380 : 822-832, 2019

44 du Bois A, "2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)" 16 (16): viii7-viii12, 2005